We read with great interest the recent paper by Wright et al. 1 The authors report that Prep1/Pbx2 transcription factor complexes differentially bind to an oligonucleotide that encompasses the À2578 single nucleotide polymorphism (SNP) in the distal regulatory region of the chemokine gene CCL2 (MCP-1). By contrast to the differential binding of Prep1/Pbx2 transcription factor complexes to this SNP, Wright et al.
1 also report that they were unable to reproduce our previous observation that there is differential binding of the IRF-1 transcription factor to the same CCL2 SNP. 2 Understanding the reasons for this discrepancy is important because it is a functional polymorphism and multiple studies have replicated our original observation that the À2578G CCL2 allele is associated with increased protein expression. 2 Furthermore, in addition to our original observation that this polymorphism is associated with an increased risk of HIV-associated dementia, 2 others have found the À2578G CCL2 allele to be a genetic susceptibility factor for many other diseases, including coronary artery disease. [3] [4] For these reasons, we sought to understand the basis of why Wright et al.
1 were unable to reproduce the differential binding of IRF-1 to the À2578 A/G SNP in CCL2 as reported originally by Gonzalez et al. 2 We considered that this discrepancy might have arisen from two sources: first, differences in the choice/length of the CCL2 sequences surrounding the SNP site that were used to design the oligonucleotide probes employed in electrophoretic mobility shift assays and antibody supershift assays ( Figure 1a ) and second, differences in the cellular source of the transcription factor, because Wright et al. and Gonzalez et al.
2 used nuclear extracts derived from the U87MG and MG-63 osteoblastic cell lines, respectively. Wright et al.
1 detected IRF-1 in the U87MG cell line by western blotting, and using antibody supershift assays, they found that IRF-1 bound to an oligomer, which contained the consensus sequences for the interferonstimulated response element. The latter observation sug- In panels b and c, IRF-1 binds with greater affinity to the À2578A-bearing oligomer than the À2578G-bearing oligomer, regardless of whether the sequences in these oligonucleotide (oligo) probes correspond to those used by Gonzalez et al. 2 or Wright et al.
1
(denoted along the right-sided Y-axis). In panels b and c, in vitro transcription and translations (IVTT) of the IRF-1 cDNA and antibody supershift experiments were performed as described previously. 5 Briefly, radiolabeled oligomers that spanned the À2578A/G polymorphism or contained the consensus IRF-1-binding motif were incubated with in vitro translated IRF-1 in the presence of binding buffer, poly(dI:dC), and 2 ml of the indicated Abs for 45 min before resolution on native polyacrylamide gels. The antibodies used were rabbit isotype control (sc-2027), anti-p65 (sc-109 X) and anti-IRF-1 (sc-497 X), and they were all obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Gels were dried and exposed overnight to X-ray film.
gested that the lack of IRF-1 transcription factor is not an explanation for their failure to detect the binding of IRF-1 to the sequences surrounding the CCL2 SNP. To exclude that the source of the nuclear extract is a confounding factor that accounts for the discrepancy observed, we performed electrophoretic mobility shift assays using in vitro transcribed and translated IRF-1 transcription factor. Confirming our previous results, 2 the 2578A-bearing oligomer bound to in vitro translated IRF-1 with greater affinity than the 2578G-bearing oligomer (Figure 1b) . Additionally, the IRF-1 protein that was bound to the CCL2 oligonucleotide probe used by Gonzalez et al. 2 was specifically supershifted by an anti-IRF-1 antibody but not by control antibodies (Figure 1b) . Similar results were detected when we performed identical experiments with the CCL2 oligonucleotide probe used by Wright et al.
1 (Figure 1c ). Collectively, these findings, using in vitro translated IRF-1, show that this transcription factor binds with differential affinity to the CCL2 gene sequences that encompass the 2578 A/G SNP, regardless of the different oligonucleotide probes used in these assays. Also these results suggest that the region spanning this polymorphism can bind IRF-1 in the absence of other transcriptional cofactors or coactivators. Hence, the suggestion by Wright et al.
1 that the region encompassing the 2578 A/G SNP in CCL2 does not function as an interferonstimulated response element may need revision.
